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Summary Serum CA 125 regression after cytoreductive surgery and during the first three courses of
chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors.
Various methods reported in the literature to calculate a CA 125 half-life value were compared. Using two
exponential regression models (Van der Burg et al., 1988; Buller et al., 1991), mean half-lives in stage I-II
patients after complete cytoreductive surgery were respectively 10.7 days (range: 5-23) and 9.8 days (range:
7-15). Within stage III-IV patients, a significant positive correlation was seen between survival and (a) stage
III (P = 0.002), (b) residual tumour 1 cm (P = 0.02), (c) CA 125 normalisation after three courses (P = 0.003)
and (d) CA 125 half-life < 20 days (P = 0.02-0.004, depending on the method used for half-life calculation).
The median survival times of patients with and without a CA 125 normalisation after three courses were 27
and 14 months respectively (P = 0.003). When using the model of Buller et al. patients with a CA 125
half-life < 20 days had a median survival of 28 months compared to a median survival of 19 months for
patients with CA 125 half-lives> 20 days (P = 0.004). Half-life calculations only showed a significant correla-
tion with survival, if pre-surgery CA 125 levels were used as a baseline.
In a survival analysis using the Cox proportional hazards model, stage of disease was the most predictive
variable for survival (P = 0.006). The only additional independent prognostic factor for survival was the CA
125 half-life calculated according to Buller [derived from the formula: CA 125 = exp. [i-s x (days after
surgery)], in which i is the y-axis intercept and s is the slope of the CA 125 regression curve]. A CA 125
half-life <20 days vs >20 days calculated using this formula, provides an independent prognostic factor for
survival in stage III-IV patients early in the course of therapy (P= 0.04).
The cancer antigen CA 125 is an established serum tumour
marker for monitoring of ovarian cancer patients. In most
patients, CA 125 serum levels correlate well with the clinical
course of the disease during therapy (Kenemans et al., 1988;
Jacobs & Bast, 1989). Current treatment results are reached
at the expense of extensive cytoreductive surgery followed by
intensive, prolonged poly-chemotherapy. Usually, this is con-
tinued until second-look surgery unless progressive disease
becomes evident. Cytotoxic therapy is often accompanied by
severe side effects. It is of major importance that non-
responders to chemotherapy are identified early in the course
of treatment. This allows a timely change in the cytostatic
agents used, whereas the use of further ineffective toxic
chemotherapy can be avoided.
In recent studies, attempts have been made to predict on
the basis of serial CA 125 levels the effect of first-line
chemotherapy as defined by time to tumour progression or
overall survival. Canney et al. first noted that in patients with
regressing CA 125 serum levels, a shorter CA 125 half-life
correlated with a good clinical response to therapy (Canney
et al., 1984). Observations by Lavin et al., indicated that a
failure of CA 125 to regress to normal after three courses of
chemotherapy, predicted persistent disease after completion
of therapy (Lavin et al., 1987). In addition, the percentage
change after one course of chemotherapy was reported to be
related to progression-free survival (Rustin et al., 1989)
although this was not confirmed by others (Redman et al.,
1990).
Van der Burg et al. first reported a CA 125 half-life of
more than 20 days to be associated with a shorter median
time to progression (Van der Burg et al., 1988). Recently, CA
125 half-lives were computed using an exponential regression
model utilising all CA 125 measurements available between
surgery and either CA 125 normalisation, or the lowest CA
125 value obtained. Employing this model, promising results
in predicting therapy efficacy have been reported (Buller et
al., 1991).
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To further evaluate the role of CA 125 regression early in
the course of therapy and to test the above mentioned
models for calculating the CA 125 half-life, a retrospective
study was carried out using CA 125 measurements in the
interval between cytoreductive surgery and the completion of
three courses of chemotherapy. The predictive significance of
a CA 125 normalisation and that of the calculated CA 125
half-life value were studied in relation to survival and in
combination with other known risk factors in ovarian cancer.
Materials and methods
Patients
Sixty patients with ovarian cancer were included in the pres-
ent study (median age: 61 years, range: 32-81). All patients
underwent primary cytoreductive surgery between July 1984
and December 1990. Surgery was performed at the Free
University Hospital Amsterdam or at the University Hospital
of Nijmegen, the Netherlands. Staging was performed ac-
cording to FIGO recommendations (Kottmeier, 1976). Seven
patients were classified as stage I, 5 patients as stage II, 37 as
stage III and 11 patients as having stage IV disease. Patient
characteristics are summarised in Table I.
Patients without available CA 125 pre-surgery levels or
with pre-surgery values within the normal range
(<35 U ml-') were excluded. Patients with a double tumour,
a previous history of malignancy or a non-epithelial ovarian
malignancy were also excluded. Following initial extensive
cytoreductive surgery all but three patients received cis-platin
or carboplatin containing combination chemotherapy. The
remaining three single cases with stage I, II and stage III
disease received 2-12 cycles of melphalan mono-
chemotherapy.
Four patients had progressive disease during first-line
chemotherapy and treatment was stopped after two (n = 1)
and after three coirses (n = 3). The median interval between
surgery and the first course of chemotherapy was 20 days
(range: 13-72). At closure of the study 25 patients were
alive, including all 12 stage I-II and 13 stage III patients
with a median follow-up of 31 months (range: 8-87 months).
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Table I Patient characteristics
FIGO stage Tumour grade
I 7 1 3
II 5 2 12
III 37 3 42
IV 11 unknown 3
Histology Residual tumour
serous 33 none 8
endometrioid 10 microscopic 6
adenocarcinoma 9 <1 cm 19
mucinous 3 1-2 cm 9
clear cell 3 >2cm 18
mixed epithelial 1
malignant Brenner I
Serum samples
A total of 346 serum samples were collected from 60 patients.
CA 125 levels were measured before surgery (n = 60),
between surgery and the first course of chemotherapy
(n = 141) and after course I (n = 50), after course II (n = 44)
and after course III (n = 51) respectively. CA 125 was
assayed using the immunoradiometric assay CA 125 provided
by Centocor (Malvern, PA, USA) according to the manufac-
turer's instructions (Bast et al., 1983). The 35 U ml' level
was used as cut-off value.
Calculations ofthe CA 125 half-life
The various methods used to calculate the CA 125 half-lives
tl/2 (a), tl/2 (b), tl/2 (c) and tl/2 (d) are illustrated in Figure
1.
log CA 125
Surg ct
a~~' -- ~~t1/2(d)
t1/2 (c)4 t '
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log 35
CA 125 half-lives were calculated using the formula as
described by Van der Burg et al., 1988: tl/2 = dt/21og (CA
125-1/CA 125-2); in which CA 125-1 is the CA 125 value
before chemotherapy (II) and CA 125-2 is the first normal
CA 125 value or the lowest CA 125 value if CA 125 did not
normalise within 3 months after the start of chemotherapy
(III). This half-life was named tl/2 (a).
In addition, using the same formula, CA 125 half-lives
were calculated using pre-surgery levels as a baseline value (I)
and taking as the second sample either the first normal CA
125 value or the lowest CA 125 value when no normalisation
occurred within 3 months from the start of therapy (III). In
this case, surgery was considered as the start of therapy and
the estimated half-life calculated this way is referred to as
tl/2 (b). The CA 125 half-life calculated using again the
pre-surgery level as a baseline (I) and taking the pre-
chemotherapy CA 125 level as the second sample (II) is
referred to as tl/2 (c).
Finally, the CA 125 half-life was calculated using the
exponential regression model according to Buller et al., 1991
based on the formula: CA 125 = exp. [i-s x (days after
surgery)]; where i is the y axis intercept and s is the slope of
the regression curve. The half-life is calculated from the slope
using the formula: tl/2 = 0.693/s. In this regression analysis,
pre-operative as well as all post-operative CA 125 levels were
included until either normalisation or until the lowest CA
125 value had been reached if an increase occurred during
chemotherapy. This half-life is referred to as tl/2 (d).
Statistical methods
CA 125 serum levels of stage I-II patients and stage III-IV
patients were compared using the Mann-Whitney test. Statis-
tical analysis included least-squares regression analysis of CA
125 levels as a function of other on study prognostic
Days after surgery
Figure 1 Methods for half-life calculations. I = pre-surgery CA 125 baseline value, II = pre-chemotherapy CA 125 baseline value,
III = first normal CA 125 value or lowest CA 125 value in the case of a CA 125 rise. surg = start of surgery, ct = start of
chemotherapy. For tl/2 a, sample II is the baseline value and sample III is used as the second sample, for tl/2 b, sample I is the
baseline value and sample III is used as the second sample and for tl/2 c, sample I is the baseline value and sample II is used as the
second sample. For the calculation of tl/2 d, all available CA 125 values were used (0).CA 125 HALF-LIFE IN OVARIAN CANCER 1363
variables. Initial univariate analysis of potential prognostic
variables for survival time was done according to Kaplan-
Meier. Differences between two curves were tested using the
log rank test. Survival time was truncated at 3 years because
of the lack of follow-up data after this period. Two year
survival rates were compared for each prognostic variable
and the Fisher exact test was used to test differences between
groups. To evaluate adjusted prognostic factors, a multiple
regression analysis was performed using the Cox propor-
tional hazards model (Dixon, 1983).
Results
In stage I-II patients, pre-operative CA 125 serum levels
were significantly lower compared to CA 125 levels in stage
III-IV patients (median: 135 U ml-' vs 2000 U ml-',
p = 0.0003). Serum CA 125 levels, measured after surgery
before the start of chemotherapy correlated with residual
tumour after surgery (R = 0.415, P = 0.001).
Half-lives marked with an asterix refer to cut-off levels
based on the mean + 2SD in stage I-II patients. Serum
levels used for half-life calculations are specified in the text.
In stage I-II patients no cases of progressive disease, nor
deaths, were observed during the study period. In stage
III-IV patients 35 out of 48 patients died with a median
survival time of 20 months (range 3-45 months). As a
consequence, prognostic factors influencing survival were
exclusively evaluated in patients with stage III-IV disease. In
the group of stage III-IV patients absolute pre-surgery and
pre-chemotherapy CA 125 levels did not correlate with sur-
vival.
Table II shows the survival times related to different prog-
nostic variables. All stage IV patients had died of ovarian
cancer after a 3 year follow-up. Overall survival time was
significantly influenced by stage (P = 0.002) and residual
tumour after cytoreductive surgery (P= 0.02). This latter
correlation was only seen when comparing a diameter,( 1 cm
vs a largest tumour deposit> 1 cm. If a 2 cm limit was taken
as discriminator, no statistical significance was reached
(p = 0.06).
CA 125 normalisation was evaluated as a prognostic factor
after one, two and three courses of chemotherapy. Nor-
malisation of CA 125 serum levels (35 U ml1' after two
courses ofchemotherapy showed a borderline significant cor-
relation with survival (P = 0.05). This correlation became
evident when CA 125 levels after three courses of
chemotherapy were studied (p =0.003). The median survival
times of patients with and without a CA 125 normalisation
after three courses were 27 and 14 months respectively,
(P = 0.003, Figure 2).
The CA 125 half-life tl/2 (a) did not correlate with sur-
vival (P = 0.274). In contrast, tl/2 (b) and tl/2 (c) <20 days
had a significantly better survival than patients with longer
CA 125 half-lives (P = 0.015 and P = 0.024 respectively). The
tl/2 (d) calculated according to the model of Buller et al.,
showed the best correlation with overall survival with median
survival times of 28 and 19 months for patients with a CA
125 half-life (20 days vs patients with longer CA 125 half-
lives (P = 0.004, Figure 3).
For each type of half-life calculation the prognostic value
was also tested at additional cut-off levels of 10, 30 and 40
days. No better correlation with survival was observed using
these cut-off levels (data not shown).
In stage I-II patients all macroscopic tumour had been
removed successfully and in all cases CA 125 normalised. To
study CA 125 regression in this particular group of patients,
CA 125 half-life was calculated using the same methods as
described before. These 'ideal' CA 125 half-lives, reflecting
CA 125 regression in the absence of macroscopic tumour, are
summarised in Table III.
As the upper limit of normal CA 125 regression, mean tl/2
plus twice the standard deviation in stage I-II patients was
chosen and compared to the half-lives found for stage III-IV
patients. In this way, only the half-lives tl/2 (b) at a cut-off
of 32.6 days and tl/2 (d) at a cut-off of 16.5 days
significantly correlated with overall survival in stage III-IV
patients (P = 0.03 and P = 0.007, respectively). These half-
lives are referred to as tl/2 (b*) and tl/2 (d*) in Table II.
Two year survival rates in relation with significant prog-
nostic variables are shown in Table IV. For some variables,
patient numbers were lower compared to patient numbers in
Table II due to censored data. Again, patients with a CA 125
normalisation after two and three courses showed
significantly better survival rates. The same was found for
tl/2 (d)<20 days and tl/2 (d*)< 16.5 days. Two years sur-
vival rates (in %) were significantly better for those patients
with CA 125 half-lives below, respectively, 20 days (63%)
and 16.5 days (66%).
Finally, a survival analysis was performed, entering all
Table II Results of the log rank test on survival curves
Variable n M x2 p Variable n M x2 p
Stage CA 125 III 7
III 37 9.70 0.002 < 35 U ml-' 21 8.90 0.003
IV 11 >35 Uml-' 20
Histology - tl/2 (a) 5
serous 30 0.82 ns < 20 days 27 1.20 ns
rest 18 >20 days 16
Grade 2 tJ/2 (b) 5
3 37 0.001 ns < 20 days 29 5.92 0.02
1+2 9 >20 days 14
Tumour rest - tJ/2 (c) 2
(2cm 30 3.44 0.06 (20 days 26 5.10 0.03
>2cm 18 >20 days 20
Tumour rest - tJ/2 (d) 16
<1 cm 21 5.34 0.02 < 20 days 18 8.50 0.004
>I cm 27 >20 days 14
CA 125 I 8 tl/2 (b*) 5
(35Uml-' 8 10.00 ns (32.6 days 34 5.01 0.03 >35Uml-' 32 >32.6 days 9
CA 125 II 13 tJ/2 (d*) 16
< 35 Uml-' 15 3.82 0.05 < 16.5 days 14 7.28 0.007 >35Uml-' 20 >16.5 days 18
n = number of patients, M = missing values, ns = not significant.
CA 125 I, II, III: CA 125 levels after respectively one, two and three courses.
tl/2 (a), tl/2 (b), tl/2 (b*) and tl/2 (c): half-life calculations using the formula tl/2 = dt/21og(CA 125-1/CA 125-2).
tl/2 (d) and tl/2 (d*): half-life calculations using the formula CA 125 = exp. [i-s x (days after surgery)].
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Figure 2 Survival curves for patients with a CA 125 normalisation ( < 35 U ml-') after three courses vs patients without a CA 125
normalisation.
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Figure 3 Survival curves for patients with a CA 125 half-life < 20 days vs patients with a CA 125 half-life>20 days. Half-lives
[tl/2 (d)] were calculated using the formula: ln [serum CA 125 = i-s (days after surgery)].
significant prognostic variables as covariates in a Cox Pro-
portional Hazards model. Stage of disease provided the best
correlation with overall survival (P = 0.006). Of all other
variables which showed a significant correlation with survival
in the univariate analysis (Table II), only tl/2 (d) could
further improve survival correlation (P = 0.04). Thus, the
calculated half-life according to the formula of Buller et al.
using a cut-off of 20 days, was the only additional indepen-
dent prognostic factor for survival in addition to FIGO
stage.
In this study the prognostic value ofearly CA 125 regression
following cytoreductive surgery and during first-lineCA 125 HALF-LIFE IN OVARIAN CANCER 1365
Table III CA 125 half-lives (in days) in stage I-II ovarian cancer
patients
n Mean SD Cut-off
tl/2 (a) 9 10.7 6.16 23
tl/2 (b) 9 14.4 9.12 32.6
tl/2 (c) 11 36.5 38.99 112.5
tl/2 (d) 5 9.8 3.34 16.5
Mean, standard deviation (SD) and derived cut-off values
(mean + 2SD) are listed. n = number of patients for whom a half-life
could be calculated. tl/2 (a), tl/2 (b) and tl/2 (c): half-life
calculations using the formula: tl/2 = dt/21og (CA 125-1/CA 125-2).
tl/2 (d): half-life calculated using the formula: CA 125 = exp.
[i-s x (days after surgery)]. Serum levels used for half-life calculations
are specified in the text.
chemotherapy in ovarian cancer was assessed. Patients with
stage III-IV ovarian cancer and a CA 125 normalisation
after three courses ofchemotherapy and those with a CA 125
half-life <20 days had a significant better prognosis than
patients who had not normalised after the third course or
who had a CA 125 half-life>20 days. This is in accordance
with previous reports (Lavin et al., 1987; Sevelda et al., 1989;
Mogensen et al., 1990; Redman et al., 1990).
In one study, the risk of dying of ovarian cancer for those
patients with elevated CA 125 levels 3 months after surgery
was three times as high as for patients whose serum levels
had normalised (Sevelda et al., 1989). However, a CA 125
normalisation remains of limited predictive value for the
definitive chance ofcure, as Mogensen et al. reported that 23
out of 47 patients with residual tumour at second-look had
shown normal CA 125 serum levels after three courses of
chemotherapy (Mogensen et al., 1990). In the present study,
5 out of 17 stage III-IV patients died within 2 years after
primary surgery despite a CA 125 normalisation after three
courses of chemotherapy.
Mogensen subdivided patients according to absolute CA
125 serum levels after three courses of chemotherapy.
Significantly different survival rates were observed for
patients with CA 125 levels,lOUml1', 11-l0OUmlh'
and> 100 U ml-' independently of other prognostic factors
(Mogensen, 1992). However, even in the group with CA 125
values < 10 U ml-', 50% died within 5 years after surgery. In
his study, Mogensen used both the Abbott RIA and Abbott
EIA. Reported CA 125 levels will be different when using the
original Centocor CA 125 RIA since there are considerable
Table IV Significant prognostic
differences between the various assays available (Yedema et
al., 1992a).
As shown recently, the time interval within which mean
CA 125 serum levels differ significantly between therapy res-
ponders and non-responders can be as short as 1 to 4 weeks
after surgery (Cruickshank et al., 1992). However, within the
group of patients with residual disease>2 cm, a discrimina-
tion between responders and non-responders could not be
made that early.
Using pre-chemotherapy CA 125 baseline levels, CA 125
half-life values have been reported to be inversely related to
the duration of progression free survival and overall survival
(Van der Burg et al., 1988; Hawkins et al., 1989; Hogberg &
Kagedal, 1990). This observation could not be confirmed in
our study. The timespan between surgery and moment of
sampling may have influenced results in our study and those
reported by others. Cytoreductive surgery itself may cause a
transient CA 125 rise (Yedema et al., 1993). This effect can
last for at least 2 weeks and is predominantly seen if pre-
surgery levels are relatively low. As a result, if CA 125
sampling has been performed shortly after laparotomy, this
baseline value may not be a reliable parameter. Median time
between surgery and pre-chemotherapy sampling was 14 days
in our study group. No exact data concerning this aspect are
available from other studies (Hawkins et al., 1989, Hogberg
& Kagedal, 1990; Van der Burg et al., 1988). Furthermore,
patient selection may explain these differences. Once enrolled
in the present study, no patients were excluded while others
only included patients showing a favourable response to
therapy (Hawkins et al., 1989; Hogberg & Kagedal, 1990)
thus excluding patients with progressive or stable disease.
While we studied only stage III-IV patients, Van der Burg
included a large portion of stage I-TI patients in her study
group (Van der Burg et al., 1988). These patients will have a
low progression rate and prolonged survival and CA 125 is
expected to normalise within a short time once chemotherapy
is initiated. Consequently, patients with early stage I-IT
disease will be over-represented in the short half-life group.
We found a significant correlation between CA 125 half-
life and survival only if pre-surgery levels were taken as a
baseline value. These data are in agreement with those of
others using pre-surgery baseline values (Hunter et al., 1990;
Willemse et al., 1991).
The best correlation between the CA 125 half-life and
survival was provided using the exponential regression model
of Buller et al. (Buller et al., 1991). In their study, CA 125
half-life predicted progressive disease and lack of respon-
variables and
follow-up
survival percentages at 2 years
Variable n deaths % survival P Odds ratio CI
Stage
III 33 17 0.45 0.03 8.47 (0.96-74.6)
IV 10 9 0.10
Tumour rest
< 1 cm 18 7 0.61 0.02 4.98 (1.33-18.6)
>I cm 25 19 0.24
CA 125 II
< 35 U ml-' 12 4 0.67 0.03 5.60 (1.16-27.1)
>35Uml-' 19 14 0.26
CA 125 III
< 35 U ml-' 17 5 0.71 0.001 12.80 (2.55-64.4)
>35 Uml-' 19 16 0.16
tl/2 (d)
<20 days 16 6 0.63 0.01 9.17 (1.49-56.3)
>20 days 13 11 0.15
tJ/2 (d*)
< 16.5 days 12 4 0.66 0.01 9.33 (1.65-52.6)
>16.5 days 17 14 0.18
n = number of patients. Odds ratios and 95% confidence intervals (CI) are included CA
125 II, III: CA 125 levels after respectively two and three courses. tl/2 (d) and tl/2 (d*):
half-life calculations using the formula: CA 125 = exp. [i-s x (days after surgery)]. The
half-life marked with an asterisk refers to a cut-off based on the mean + 2SD in stage I-II
patients (Table III). Serum levels used for half-life calculations are specified in the text.1366 C.A. YEDEMA et at.
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FIgure 4 CA 125 half-life [tlI2 (d)] and survival in stage III-IV patients. Closed circles symbolise deceased patients. Open circles
symbolise survivors.
siveness to chemotherapy. In our multiple regression analysis
this factor was, in addition to stage of disease, the only
independent prognostic variable in predicting survival. Thus,
our data show that this model can be used as an independent
predictor of survival.
The half-life of CA 125 after complete debulking is a
particular point of interest. Canney et al. found a CA 125
half-life of 4.8 days based on one single observation (Canney
et al., 1984). Buller et al. reported a mean serum half-life of
10.8 days (Buller et al., 1991) in their study population,
which included a substantial portion of completely resected
stage III-IV patients, some of whom might suffer from early
tumour recurrence. This occurred in two stage III patients
from the present series at 9 and 18 months after complete
cytoreductive surgery. All stage I-II patients in the present
study who underwent complete cytoreductive surgery were
without evidence of disease in the follow-up period (median
29 months, range 8-85). In these 12 patients, the mean CA
125 half-life tl/2 (d) according to Buller was 9.8 days. At a
cut-off of 16.5 days (mean + 2SD) univariate analysis showed
a significant correlation with survival, while in a multivariate
model, no independent prognostic value could be found
(P = 0.09). We believe that CA 125 regression in stage I-II
patients deserves further attention to obtain an estimate of
the ideal CA 125 regression curve which could serve as a
reference for patients with advanced disease.
In the present study there were short term and long term
survivors in respectively the short CA 125 half-life (,<20
days) and the long CA 125 half-life group (>20 days)
(Figure 4). Also in previous studies based on absolute CA
125 values, overlapping values between good and poor re-
sponders were frequently found. The CA 125 half-life based
on the exponential regression model according to Buller was
the only variable with a significant prognostic value other
than stage in the multivariate analysis. Whether or not the
CA 125 half-life based on serial measurements early during
therapy is a better discriminator between good and poor
responders than single CA 125 measurements before therapy
and after three courses remains to be elucidated. A large
scale multi-centre study might give the answer which CA 125
response at what stage during therapy provides the best
estimation of the survival time to be expected.
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